company mission
Pluri's mission barely moved between July 25, 2022 and January 27, 2023. In both statements, the company argues that its 3D cell-expansion platform can turn cell biology into practical, scalable products, and in both it ties that claim to two big outcomes: improving global wellbeing and improving sustainability. The core structure stays the same: one platform, many industries, large-scale expansion, lower cost, broad ambition. What changed is mostly emphasis and wording. The 2022 version describes the platform as a foundational technology that can power innovation across medicine, pharma, food tech, and other sectors. The 2023 version sharpens the branding around Pluri itself, calls the technology patented, adds the phrase about "harness[ing] the wisdom of nature," and leans harder into Pluri as a global leader. It also names agri-tech alongside food tech and pharma. That looks more like positioning polish than a real mission shift. The evidence is thin because we only have two website snapshots six months apart, and both are high-level corporate statements. They tell us how the company wanted to describe its mission in public, not whether management changed its internal priorities or capital allocation. Based on these two entries alone, the best read is continuity with slightly more assertive marketing language.